Viridian Therapeutics
VRDN
29.96
-1.48
-4.71%
Viridian Therapeutics
US · VRDN
#2731 by market cap
Listed 1970
29.96
-1.48
-4.71%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Rating change
Wedbush Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $43Market Newswire · 2026/8/5
-
Rating change
Stifel Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $40Market Newswire · 2026/7/1
-
Wells Fargo Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $34Market Newswire · 2026/11/6
-
Rating change
RBC Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $38Market Newswire · 2026/10/9
-
Rating change
Truist Financial Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $39Market Newswire · 2026/8/13
-
Rating change
Wells Fargo Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $31Market Newswire · 2026/10/14
-
Rating change
Evercore Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $26Market Newswire · 2026/10/31
-
Rating change
LifeSci Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $35Market Newswire · 2026/10/3
-
Rating change
RBC Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $38Market Newswire · 2026/9/22
-
H.C. Wainwright Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $40Market Newswire · 2026/11/10
-
Rating change
Stifel Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $40Market Newswire · 2026/8/14
-
A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $33 to $42Market Newswire · 2026/11/6
-
Wells Fargo Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $39Market Newswire · 2026/11/10
-
A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $40 to $53Market Newswire · 2026/11/5
-
Rating change
Goldman Sachs Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $40Market Newswire · 2026/8/20
-
Rating change
Truist Financial Maintains Viridian Therapeutics(VRDN.US) With Buy RatingMarket Newswire · 2026/9/1
-
Rating change
A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $22 to $41Market Newswire · 2026/8/7
-
Rating change
Jefferies Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $30Market Newswire · 2026/6/30
-
Rating change
Truist Financial Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $39Market Newswire · 2026/8/7
-
Rating change
Wedbush Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $41Market Newswire · 2026/11/4
-
Rating change
A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $22 to $43Market Newswire · 2026/6/30
-
Rating change
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Fortrea Holdings Inc. (FTRE)TipRanks · 2026/6/29
-
Rating change
A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $22 to $35Market Newswire · 2026/6/29
-
Rating change
Wells Fargo Maintains Viridian Therapeutics(VRDN.US) With Hold Rating, Maintains Target Price $20Market Newswire · 2026/6/17
-
Rating change
Wedbush Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $32Market Newswire · 2026/6/28
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Viridian Therapeutics discussion 0 comments